Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
Published version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Abstract Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive. Using a genome-wide loss-of-function screen, we identified that impaired death receptor signaling in ALL led to rapidly progressive disease despite CART19 treatment. This was mediated by an inherent resistance to T-cell cytotoxicity that permitted antigen persistence and was subsequently magnified by the induction of CAR T-cell functional impairment. These findings were validated using samples from two CAR T-cell clinical trials in ALL, where we found that reduced expression of death receptor genes was associated with worse overall survival and reduced T-cell fitness. Our findings suggest that inherent dysregulation of death receptor signaling in ALL directly leads to CAR T-cell failure by impairing T-cell cytotoxicity and promoting progressive CAR T-cell dysfunction. Significance: Resistance to CART19 is a significant barrier to efficacy in the treatment of B-cell malignancies. This work demonstrates that impaired death receptor signaling in tumor cells causes failed CART19 cytotoxicity and drives CART19 dysfunction, identifying a novel mechanism of antigen-independent resistance to CAR therapy. See related commentary by Green and Neelapu, p. 492.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, CRISPR screening showed that loss of tumor-associated death receptors leads to CAR T-cell resistance.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [30]
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096 · cited 1×
“Downstream analysis and visualization was done using HOMER (44) and deepTools2 (45).”
MethodBuenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422 · cited 2×
“Purification of transposed DNA was completed with DNA Clean and Concentrator (Zymo), and fragments were barcoded with ATAC-seq indices (39).”
BackgroundMethodTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 2×
“Death Receptor Gene Expression Correlates with Clinical Outcomes after CAR T-cell Therapy in ALL In light of these preclinical observations, we investigated the association between leukemia expression of death receptor genes and clinical outcomes after treatment with tisagenlecleucel, a CD19 CAR T-cell clinical produc…”
MethodSelf-citation
Cited by
Items 101–200 of 295
Advances in chimeric antigen receptor T cells
Beyar‐Katz, O., & Gill, S. I. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000614 · Cited by 29
“Additional factors to be considered include the quality of the T cells [44 && ,64–66] and cancer cell sensitivity to T-cell-mediated killing [67].”
BackgroundNew insights into CAR T cell-mediated killing of tumor cells
Espie, D., & Donnadieu, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016208 · Cited by 33
“In addition, recent articles have shown that tumor cells can resist CAR T-cell killing in various ways such as the capacity to repair their membranes following a ‘hit’ from cytotoxic T-cells (8) as well as the presence of mutations in apoptosis pathways (9).”
BackgroundMechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Nasiri, F., Kozani, P. S., Salem, F., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03697-y · Cited by 31
“…differentiation status) and the disruption of death receptor signaling cascades due to the loss of TRAIL2 and FADD by malignant cells, which renders them resistant to the tumoricidal effects of CAR-T cells, also contribute to the emergence of resistance to CAR-T cell therapies [169, 170].”
CAR-T cell persistence in the treatment of leukemia and lymphoma
Gupta, A., & Gill, S. I. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1913146 · Cited by 31
“More recently, impaired death receptor signaling in ALL has been proposed as another mechanism driving early dysfunction of CAR-T cells [42].”
BackgroundCAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
Ali, A., Goy, A. H., & Dunleavy, K. M. (2022) · Blood · doi:10.1182/blood.2022016226 · Cited by 28
Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies
Castellanos-Rueda, R., Roberto, R. B. D., Schlatter, F. S., & Reddy, S. T. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.03.005 · Cited by 24
Martínez-Rubio, Á., Chulián, S., Goñi, C. B., Martínez, A. P., Ramírez, M. R., Navarro‐Zapata, A., Ferreras, C., Pérez‐García, V. M., & Rosa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126371 · Cited by 32
“The literature suggests that this could be induced by leukemic cells themselves [60], which is something to explore in future works.”
BackgroundHargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 36
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Testa, U., Sica, S., Pelosi, E., Castelli, G., & Leone, G. G. M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.010 · Cited by 38
“62 A recent study identified a gene expression profile that correlates with primary resistance to CD19 CAR-T cell therapy in B-ALL samples, related to the expression of genes typically expressed in hematopoietic stem/progenitor cells while maintaining a pre-B cell phenotype.”
BackgroundTherapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
Menegatti, S., López‐Cobo, S., Galy, A. S. D., Fuentealba, J. R., Silva, L. E., Perrin, L., Heurtebise-Chrétien, S., Pottez-Jouatte, V., Darbois, A., Burgdorf, N., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01282-8 · Cited by 31
“The Fas/FasL axis is also involved in CAR T cell cytotoxicity 23 , and FasL is highly expressed by NK and CD8 + T cells in the tumour microenvironment compared with tumour and stroma cells 24 .”
Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma
Léveillé, E., & Johnson, N. A. (2021) · Cancers · doi:10.3390/cancers13092167 · Cited by 28
“Recent evidence using CRISPR knockout screens suggests that defects in the extrinsic apoptotic pathway contribute to resistance to CAR T cell and BiTE therapy in DLBCL and other hematological malignancies [176,177].”
BackgroundZheng, N.-S., Zhao, X.-Y., Wei, D., Miao, J., Liu, Z.-K., Yong, Y., Zhang, R., Guo, Y., He, L., Wang, B., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215762 · Cited by 30
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges
Ong, M. Z., Kimberly, S. A., Lee, W.-H., Ling, M., Lee, M., Tan, K.-W., Foo, J. B., Yow, H.-Y., Sellappans, R., & Hamzah, S. B. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010257212231001082741 · Cited by 34
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies
Sakemura, R. L., Cox, M. J., Hefazi, M., Siegler, E. L., & Kenderian, S. S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1894648 · Cited by 26
Yan, Z., Li, L., Fu, D., Wu, W., Qiao, N., Huang, Y., Jiang, L., Wu, D., Hu, Y., Zhang, H., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0972-8 · Cited by 28
“A gene mutation panel of 55 genes related to oncogenesis of DLBCL [11] was performed on tumor samples of 21 patients (six CR and six progressed patients at day 90 of the CD28z CAR-T trial, as well as five CR and four progressed patients at day 90 in the 41BBz CAR-T trial).”
BackgroundInfluentialHadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 30
Arunachalam, A. K., Grégoire, C., de Oliveira, B. C., & Melenhorst, J. J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101241 · Cited by 30
High-content CRISPR screening in tumor immunology
Holcomb, E. A., Pearson, A. N., Jungles, K. M., Tate, A., James, J. G., Jiang, L., Huber, A. K., & Green, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041451 · Cited by 28
“Moreover, an in vitro screen of CD19 acute lymphoblastic leukemia cells cocultured with CD19-targeted CAR T cells has found that deficiency in the death receptor apoptotic signaling pathway mediates cancer cell resistance and induces CAR T cell dysfunction (104).”
BackgroundJoy, J. D., Malacrida, B., Laforêts, F., Kotantaki, P., Maniati, E., Manchanda, R., Annibaldi, A., Hopkins, S., Garrobo-Calleja, I., Gautrot, J. E., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3007 · Cited by 25
“Birinapant was ranked as one of the top three drugs that enhanced CD19 CAR T-cell cytotoxicity against B-ALL cells (34).”
InfluentialBoosting CAR-T cell therapy with CRISPR technology
Yan, L., Gao, S., Wang, X., Zhou, X., Limsakul, P., & Wu, Y. (2024) · hLife · doi:10.1016/j.hlife.2024.06.002 · Cited by 25
“For example, genome-wide loss-of-function screening in Nalm6 tumor cells revealed that impaired death receptor signaling led to increased resistance to CD19 CAR-T treatment, which was further validated using clinical samples [163].”
Designed improvement to T-cell immunotherapy by multidimensional single cell profiling
Bandey, I. N., Adolacion, J. R. T., Romain, G., Martinez-Paniagua, M. A., An, X., Saeedi, A., Liadi, I., You, Z., Rajanayake, R. B., Hwu, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001877 · Cited by 22
“42 We utilized the differential gene expression profiling between killer and non-killer T cells to identify pathways that can enhance the survival of killer T cells directly leading to sustained and enhanced anti-tumor efficacy.”
Prime, shock and kill: BCL-2 inhibition for HIV cure
Chandrasekar, A. P., & Badley, A. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033609 · Cited by 22
“Similar to Fas, TRAIL too has been identified as a crucial regulator of CAR-T function in lymphoid malignancy (42, 43).”
BackgroundInterrogating immune cells and cancer with CRISPR-Cas9
Buquicchio, F. A., & Satpathy, A. T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.003 · Cited by 21
Vercellino, L., de Jong, D., Blasi, R. D., Kanoun, S., Reshef, R., Schwartz, L. H., & Dercle, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.664688 · Cited by 25
“Moreover, CAR T-cells’ viability and efficacy can be impaired by suboptimal stimulation leading to T cells exhaustion and relapse (14).”
BackgroundKusowska, A., Kubacz, M., Krawczyk, M., Ślusarczyk, A., Winiarska, M., & Bobrowicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031501 · Cited by 29
Apoptosis: a Janus bifrons in T-cell immunotherapy
Lee, Y. G., Yang, N., Chun, I., Porazzi, P., Carturan, A., Paruzzo, L., Sauter, C. T., Guruprasad, P., Pajarillo, R., & Ruella, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005967 · Cited by 25
“32 Our group also demonstrated that birinapant treatment improved CAR-T cells ability to eliminate B-ALL, which otherwise lacks sensitivity to extrinsic apoptosis 34 ; however, these results were obtained in vitro and in vivo validation is required to exclude toxicity on CAR T cells.”
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 27
Miao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 23
Bartoló‐Ibars, A., Uribe‐Herranz, M., Muñoz‐Sánchez, G., Arnaldos‐Perez, C., Ortiz‐Maldonado, V., Urbano-Ispizúa, Á., Pascal, M., & Juan, M. (2021) · Cancers · doi:10.3390/cancers13184664 · Cited by 21
“However, other death receptors such as BH3-interacting domain death agonist (BID) and FAS-associated death domain protein (FADD) have also been associated with CAR antitumoral function [25–27].”
Selli, M. E., Landmann, J. H., Arveseth, C. D., & Singh, N. (2023) · STAR Protocols · doi:10.1016/j.xpro.2022.101954 · Cited by 24
Relapsed ALL: CAR T vs transplant vs novel therapies
Frey, N. V. (2021) · Hematology · doi:10.1182/hematology.2021000225 · Cited by 21
IRE1 RNase controls CD95-mediated cell death
Pelizzari‐Raymundo, D., Maltret, V., Nivet, M., Pineau, R., Papaioannou, A., Zhou, X., Caradec, F., Martin, S., Gallo, M. L., Avril, T., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00095-9 · Cited by 25
“48h later, cells were treated with the indicated concentrations of CD95L for 48h. Viability was assessed using MTT assay and normalized to untreated cell values.”
Pharmacology of Chimeric Antigen Receptor–Modified T Cells
Song, E. Z., & Milone, M. C. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031720-102211 · Cited by 25
Multiplexed engineering and precision gene editing in cellular immunotherapy
Biederstädt, A., Manzar, G. S., & Daher, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063303 · Cited by 20
Challenges and optimal strategies of CAR T therapy for hematological malignancies
Zhang, Y., Yang, X., Dang, X., Zhu, Z., Qian, W., Liang, A., & Han, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002476 · Cited by 20
“of Singh et al [22] performed a loss-of-function screening in B-ALL and B-lymphoma cell lines and demonstrated that impaired death receptor signaling contributed to the dysfunction of CAR T cells, which was independently con rmed by Dufva .”
Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells
Pourzia, A. L., Olson, M., Bailey, S. R., Boroughs, A. C., Aryal, A., Ryan, J. A., Maus, M. V., & Letai, A. G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05727-x · Cited by 21
Szymura, S. J., Wang, L., Zhang, T., Cha, S.-C., Song, J. Y., Dong, Z., Anderson, A., Oh, E., Lee, V., Wang, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50880-2 · Cited by 22
“S2F) 44 .”
Aboelella, N. S., Brandle, C., Okoko, O. D., Gazi, M. Y., Ding, Z., Xu, H., Gorman, G. S., Bollag, R. J., Davila, M. L., Bryan, L. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004938 · Cited by 21
“51 52 Based on these published studies and our current data, we put forth the hypothesis that simultaneous upregulation of TRAIL in donor T cells and DR5 in cancer cells can further magnify cell death in cancer cells.”
Kim, S. J., Yoon, S. E., & Kim, W. S. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0388 · Cited by 22
“When tumor cells harbor impaired death receptor signaling, such as the lack of proapoptotic molecules, they can resist CAR T-cell treatment [76].”
BackgroundImproving CAR T-cells: The next generation
Marple, A., Bonifant, C. L., & Shah, N. N. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.002 · Cited by 20
Azcona, M. S. R., Monaco, G., Whitehead, M., Kaufmann, M. M., Alzubi, J., Cathomen, T., & Mussolino, C. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102618 · Cited by 20
“24,25 We therefore modified our protocol and replenished the culture with PSMA-positive cells (C4-2 cells) every 3 days for a period of 12 days (Figure 3A).”
Genome editing of immune cells using CRISPR/Cas9
Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 26
Im, N. G., Guillaumet-Adkins, A., Wal, M., Rogers, A. J., Frede, J., Havig, C. C., Yang, J., Anand, P., Stegmann, S. K., Waldschmidt, J. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0626 · Cited by 17
Xu, H., Li, N., Wang, G., & Cao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110028 · Cited by 19
“(49) found that defects in death receptor signaling pathways in lymphomas lead to resistance to CART19 and consequently reduced CAR T-cell function.”
BackgroundStalled CARs: Mechanisms of Resistance to CAR T Cell Therapies
Salas‐Benito, D., Berger, T. R., & Maus, M. V. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012235 · Cited by 18
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
Althaus, J., Nilius‐Eliliwi, V., Maghnouj, A., Döring, S., Schroers, R., Hudecek, M., Hahn, S. A., & Mika, T. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03443-1 · Cited by 20
“A recent study revealed downregulation of genes involved in Fas-mediated apoptosis as an important feature of primary resistance against CAR-T cells in B-ALL [10].”
BackgroundCesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 25
Masih, K. E., Gardner, R., Chou, H.-C., Abdelmaksoud, A. A., Song, Y. K., Mariani, L., Gangalapudi, V., Gryder, B. E., Wilson, A. L., Adebola, S. O., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008977 · Cited by 17
“Using CD19 targeted PacBio long-read sequencing, we detected exon 2 skipping, which has previously been associated with relapse after the initial response to CD19-CAR, in 1 case of PNR.”
BackgroundInfluentialCohen, I., Bochi-Layec, A. C., Lemoine, J., Jenks, S. A., Bayat, P., Kim, K. H., Zhao, H., Ugwuanyi, O. H., Stella, F., Ghilardi, G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adr9382 · Cited by 18
Olson, N. E., Ragan, S. P., Reiss, D. J., Thorpe, J., Kim, Y., Abramson, J. S., McCoy, C., Newhall, K. J., & Fox, B. A. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0506 · Cited by 17
“Althoughtrending,neithertheImmunosign21signaturenorthe death receptor signature (40) were signi fi cant in the month-3 CR versus PD comparison despite previous reports (11, 12). mIF con fi rmed RNA-seq observations and additionally showed a large endogenous T-cell increase post-infusion The PRE( N ¼…”
Pharmacologic Control of CAR T Cells
Caulier, B., Enserink, J. M., & Wälchli, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094320 · Cited by 17
“This arm should reveal its full potential to alleviate tumor resistance mechanisms and counteract the nonpermissive TME.”
BackgroundA convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Zhang, Z., Ho, Y.-J., Fang, X., Kim, M., Li, M., Luan, W., Hinterleitner, C., Haubner, S., Kogel, F., Pratt, E. C., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.002 · Cited by 22
High-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Sun, S., Huang, C., Lü, M., Xu, H., Yuan, Y., Zhao, W., Hu, X., Wang, B., Zhang, W., Gao, X., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0531 · Cited by 17
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Saleh, K., Pasquier, F., Bigenwald, C., de Botton, S., Ribrag, V., & Castilla‐Llorente, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216883 · Cited by 23
“Concerning CD19-negative relapse, it occurs when the CD19 antigen is lost through mutation or epigenetic alterations especially in pre-existing leukemia subclones [58–60].”
BackgroundRathinavel, T., Vasuki, S., Sindhu, S. M., Mothilal, T. M., Srimathi, V., Poornima, B., Bhuvaneswari, M., & Hariharan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01090-0 · Cited by 20
“According to Singh et al., 2020 research finding reveals that it has been demonstrated that blocking leukaemia cells' apoptotic pathways reduces their susceptibility to CAR-mediated cytotoxicity, which in turn causes CAR T cell depletion as a result of prolonged tumour exposure [66].”
Papakyriacou, I., Kutkaite, G., Bedós, M. R., Nagarajan, D., Alford, L. P., Menden, M. P., & Mao, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-47987-x · Cited by 21
“When co-cultured with chimeric antigen receptor (CAR)- modi fi ed T cells, defects in the death receptor pathways enabled leukemic cell survival and escape of T cell-mediated killing 11 .”
Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR ‐T‐Cell Therapy
Zhang, Z., Su, M., Jiang, P., Wang, X., Tong, X., & Wu, G. (2024) · Cancer Medicine · doi:10.1002/cam4.70283 · Cited by 21
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 24
Merting, A. D., Poschel, D. B., Lu, C., Klement, J. D., Yang, D., Li, H., Shi, H., Chapdelaine, E., Montgomery, M., Redman, M. T., et al. (2022) · Cancers · doi:10.3390/cancers14020361 · Cited by 17
“Moreover, FAS-dependent tumor killing by CAR-T is augmented by inhibiting or knocking out anti-apoptotic regulators or by increasing pro-apoptotic regulators of the FAS signaling pathway [11,60,61].”
BackgroundCox, W. P. J., Dautzenberg, N. M. M., Dekker, L., Klenovšek, T., Cornel, A. M., van Hoesel, M., Schenau, D. V. I., Bladergroen, R. S., Kuiper, R. P., van der Meer, L. T., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100060 · Cited by 14
“Notably, DR signaling has been implicated in antigen-independent CART19 resistance in BCP-ALL in 2 independent CRISPR screens, 17,18 one of which correlated low DR expression with adverse outcome in patients.”
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Kimman, T., Cuenca, M., Tieland, R. G., Rockx-Brouwer, D., Janssen, J., Motais, B., Slomp, A., Pleijte, C., Heijhuurs, S., Meringa, A. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59818-8 · Cited by 20
“Two separate studies used genome-wideCRISPR/Cas9knock-outscreensinB-ALLcellstorevealthatdeath receptorTRAIL-R2 (TNFRSF10B),and downstreamsignalingmolecules FADD, BID, and CASP8, mediate sensitivity to anti-CD19 CAR T cell killing 8,9 .”
The Role of Radiotherapy in Lymphoma Patients Undergoing CAR T Therapy: Past, Present, and Future
Wallington, D. G., Imber, B. S., Scordo, M., & Robinson, T. J. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2024.10.005 · Cited by 19
Marhelava, K., Krawczyk, M., Firczuk, M., & Fidyt, K. (2022) · Cells · doi:10.3390/cells11111804 · Cited by 16
“The crucial role of death receptor signaling in susceptibility to CD19 CAR-T cytotoxicity was demonstrated in a Nalm-6 B-ALL cell line in vitro model and CRISPR-based genome-wide loss-of-function screen [121,122].”
BackgroundResultKim, A. B., Chou, S.-Y., Kang, S., Kwon, E. O., Inkman, M. J., Szymanski, J. J., Andruska, N. D., Colgan, C., Zhang, J., Yang, J. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009543 · Cited by 13
“3 Although the DR pathway was named for molecules that are downstream of DRs, the majority of these molecules are also downstream of granzyme B/perforin, 21 which is a major mechanism by which CAR T cells kill their targets.”
Intracellular zinc protects tumours from T cell-mediated cytotoxicity
Lelliott, E. J., Naddaf, J., Ganio, K., Michie, J., Wang, S., Liu, L., Silke, N., Ahn, A., Ramsbottom, K. M., Brennan, A. J., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01369-4 · Cited by 17
“In line with previous studies by us and others, we identi fi ed TNF-mediated cell death as a critical mechanism by which cytotoxic T cells elicit their anti-tumour activity [5 – 7 , 14].”
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 16
“Genes involved in apoptosis regulation, such as FAS (reduced expression) and BCL2 (upregulation), play a central role and have been correlated with poor clinical responses [71–73].”
Srivastava, S., Tyagi, A., Pawar, V. A., Khan, N. H., Arora, K., Verma, C., & Kumar, V. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s474659 · Cited by 14
Mavuluri, J., Dhungana, Y., Jones, L. L., Bhatara, S., Shi, H., Yang, X., Lim, S.-E., Reyes, N., Chi, H., Yu, J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0841 · Cited by 13
“Furthermore, consistent with the findings from Singh and colleagues (23), downregulation of death receptor genes was observed in m.PR tumors compared with that in m.CR tumors (Supplementary Fig.”
Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia
Liu, Y., Wang, W., Wang, C., Deng, J., Hu, Y., Mei, H., & Luo, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572407 · Cited by 13
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura, N. B., Sim, A. J., Jain, M. D., Chávez, J. C., & Robinson, T. J. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2147919 · Cited by 11
“In-vitro functional knock out CRISPR screens of resistance in leukemia have indicated that death receptor signaling and apoptosis results in CAR T-cell resistance [22].”
BackgroundYao, S., Yin, X., Chen, T., Chen, W., Zuo, H., Bi, Z., Zhang, X., Jing, Y., Pang, L., & Cheng, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-06244-1 · Cited by 13
Zalka, C. V. (2012) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 23
Differential susceptibility and role for senescence in CART cells based on costimulatory domains
Can, İ., Siegler, E. L., Sirpilla, O. L., Manriquez-Roman, C., Yun, K., Stewart, C. M., Feigin, J. M., Rodriguez, M. L., Gutierrez-Ruiz, O. L., Ogbodo, E. J., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02371-1 · Cited by 11
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy
Zhou, W., Huang, Z., Wu, Z., Tang, M., Zhu, L., Shi, W., Wang, Q., & Feng, L. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253017 · Cited by 10
“This dysfunction of CD19-CAR-T cells indicates a novel mechanism of resistance to CAR-T cell therapy that operates independently of antigen presence [52].”
Xu, X., Yu, S., Liu, X., & Feng, Y. (2021) · Genetics Research · doi:10.1155/2021/7624346 · Cited by 10
“At present, it is considered that apoptosis is mainly mediated by two signal pathways, including the death receptor signal pathway [34] and mitochondria-independent signal pathway [35].”
BackgroundTumour Escape from CAR-T Cells
Rasche, L., Vago, L., & Mutis, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_4 · Cited by 11
Chimeric Antigen Receptor T-cell Therapy
Talleur, A. C., Myers, R. M., Annesley, C., & Shalabi, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.005 · Cited by 11
Ascierto, P. A., Avallone, A., Bifulco, C. B., Bracarda, S., Brody, J., Emens, L. A., Ferris, R. L., Formenti, S. C., Hamid, O., Johnson, D. B., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04329-7 · Cited by 11
Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement
Wu, A., Zhang, T., Yu, H., Cao, Y., Zhang, R., Shao, R., Liu, B., Chen, L., Xu, K., Chen, W., et al. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.04.002 · Cited by 9
Bharadia, H., Dabhade, A., Shah, A. C., Patel, R., Chorawala, M. R., Patel, A., & Shah, P. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02957-1 · Cited by 12
“B-ALL cell lines that are devoid of pro-apoptotic markers FADD, BID, CASP8, or TNFRSG10 were shown by Singh et al. [71] to be immune to CAR T-cell When 122 patients with DLBCL receiving standard-of-care CAR T-cell treatment had their pre-treatment plasma samples analyzed using low-pass whole-genome…”
Lu, C., Liang, L., Wu, Y., Yang, Y., Poschel, D. B., Zhao, Y., Pei, L., Yu, M., Zoccheddu, M., Bombin, S., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03543-5 · Cited by 11
Yang, Y., Louie, R. H. Y., Puc, J., Vedvyas, Y., Alcaina, Y., Min, I. M., Britz, M., Luciani, F., & Jin, M. M. (2023) · Cancers · doi:10.3390/cancers15235552 · Cited by 8
“…and TCR repertoire profiling, have played a pivotal role in identifying key genes involved in T cell cytotoxicity and dysfunction [19,20], with the characterization of CAR T cell functional states that are associated with cell products, clinical responses, and toxicities [9,21,22],…”
BackgroundApplications of single‐cell omics for chimeric antigen receptor T cell therapy
Ghaffari, S., Saleh, M., Akbari, B., Ramezani, F. M., & Mirzaei, H. R. (2023) · Immunology · doi:10.1111/imm.13720 · Cited by 10
“These results delineate how immune cell defects are not all inherent and can be acquired following tumour inception [84].”
BackgroundMethodOng, S. Y., Chen, Y., Tan, M. S. Y., Ho, A. Y. L., Hwang, W. Y. K., & Lim, F. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13964 · Cited by 7
Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies
Su, Y., Xu, X., Yang, G., Chen, B., Chen, X., Chen, Q., Lv, K., Zhang, Z., Liu, H., Qi, X., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218014 · Cited by 7
Mapping clinical CAR-T cells: insights from scRNA-seq
Meehl, M. M., Ward, M. B., & Krenciute, G. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.006 · Cited by 8
Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death
Semba, M., Takamatsu, S., Komazawa‐Sakon, S., Miyoshi, E., Nishiyama, C., Nakano, H., & Moriwaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136973 · Cited by 9
“In addition, recent unbiased clustered regularly interspaced palindromic repeat (CRISPR)-based genome-wide loss-offunction screens have identified the TRAIL-TRAIL receptor axis as a critical determinant of the therapeutic response of cancer cells to CAR-T cell immunotherapy [4,5].”
BackgroundTumor immune evasion: insights from CRISPR screens and future directions
Djajawi, T. M., Wichmann, J., Vervoort, S. J., & Kearney, C. J. (2023) · FEBS Journal · doi:10.1111/febs.17003 · Cited by 8
“This is not to say that other death receptor pathways are dispensable, since a genome-wide screen with the Brunello library identified both FADD and its downstream effector BID as a key mediator for CD-19-specific CAR T-cell killing of Nalm6 cells [49].”
BackgroundOvercoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7
Liao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
“Consistently, Singh et al. also demonstrated that treatment resistance was associated with the upregulation of exhaustion markers [95].”
BackgroundWang, Z., ZHOU, L., & WU, X. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.048564 · Cited by 6
“Conversely, guides targeting anti-apoptotic molecules such as CFLAR, TRAF2 , and BIRC2 were found to be depleted [118].”
BackgroundCAR-T cell therapy for glioblastoma: advances, challenges, and future directions
Czyżewski, W., Kuś-Budzyńska, K., Sobstyl, J., Sojka, M., Litak, J., Szaliński, T., Jezewski, M., Turek, M., Chaurasia, B. K., Mandat, T. S., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003607 · Cited by 9
“Singh et al discovered that lenalidomide, approved by the FDA in 2013 for mantle lymphoma, enhances the growth and sustained antitumor efficacy of 3C10 CAR-modified PBMCs targeting EGFRvIII in vivo [ 39 , 40 ] .”
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer
Schultz, L. M., McNerney, K. O., Lamble, A. J., Calkoen, F., Baruchel, A., Ceppi, F., Curran, K. J., Gore, L., Lamb, M. G., Maude, S. L., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01115-w · Cited by 8
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
Johnson, G. A., & Locke, F. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.07.003 · Cited by 7
Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
Nagarajan, D., Parracho, R. T., Corujo, D., Xie, M., Kutkaite, G., Olsen, T. K., Bedós, M. R., Salehi, M., Baryawno, N., Menden, M. P., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175310 · Cited by 8
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Zhang, X., Xu, K., Gale, R. P., & Pan, B. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02463-4 · Cited by 6
“Singh et al. reported that impaired death receptor signaling in tumor cells led to failure of anti-CD19 CAR T-cell cytotoxicity [45].”
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer
Yao, C., & Davis, K. L. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10232-4 · Cited by 6
“Knock-outs of FADD or BID conferred resistance to CAR-T-mediated killing, and with prolonged exposure, the resistant ALL cells induced CAR-T-cell dysfunction and exhaustion [88].”
Apoptosis, guardian of the genome: Review
Khalil, A. M. (2021) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2021.5.1.0003 · Cited by 6
Metadata
- Authors
- Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., Weitzman, M. D., Frey, N. V., Maude, S. L., Grupp, S. A., June, C. H., Gill, S., & Ruella, M.
- Affiliations
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Novartis (Switzerland) (CH)
- 5Novartis Institutes for Biomedical Research, East Hanover, New Jersey.
- Corresponding author
- Singh, Nathan
- Gill, Saar
- Ruella, Marco
- ORCID
- Singh, Nathan
- Lee, Yong Gu
- Ravikumar, Pranali
- Hayer, Katharina E.
- Hong, Seok Jae
- Lu, Xueqing Maggie
- Pajarillo, Raymone
- Agarwal, Sangya
- Kuramitsu, Shunichiro
- Orlando, Elena J.
- Mueller, Karen Thudium
- Good, Charly R.
- Berger, Shelley L.
- Shalem, Ophir
- Weitzman, Matthew D.
- Frey, Noelle V.
- Maude, Shannon L.
- Grupp, Stephan A.
- June, Carl H.
- Gill, Saar
- Ruella, Marco
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 552-567
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3003403042
- Cited by
- 295
- References
- 49
- Citations by year
- 2026: 28 · 2025: 40 · 2024: 35 · 2023: 55 · 2022: 67 · 2021: 51 · 2020: 18
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Society of Immunotherapy for Cancer Holbrook Kohrt Immunotherapy Translational Fellowship
- Breakthrough Bike Challenge Buz Cooper Scholarship
- NCI (K08CA194256, 1K99CA212302, R00CA212302, 1P01CA214278, R01CA226983)
- American Society of Hematology Scholar Award
- Mark Foundation ASPIRE award
- University of Pennsylvania-Novartis Alliance
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- acute lymphoblastic leukemia, CAR T-cell therapy, CD19, chimeric antigen receptor, death receptor signaling, T cell cytotoxicity, CAR T-cell dysfunction, loss-of-function screen, B-cell malignancies, T cell fitness
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Signal Transduction, Receptors, Death Domain, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.